A detailed history of Qube Research & Technologies LTD transactions in Elevation Oncology, Inc. stock. As of the latest transaction made, Qube Research & Technologies LTD holds 131,898 shares of ELEV stock, worth $79,138. This represents 0.0% of its overall portfolio holdings.

Number of Shares
131,898
Previous 142,725 7.59%
Holding current value
$79,138
Previous $732,000 51.37%
% of portfolio
0.0%
Previous 0.0%

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

SELL
$2.35 - $5.17 $25,443 - $55,975
-10,827 Reduced 7.59%
131,898 $356,000
Q1 2024

May 14, 2024

BUY
$0.59 - $5.13 $84,207 - $732,179
142,725 New
142,725 $732,000
Q3 2021

Nov 12, 2021

SELL
$7.66 - $16.11 $185,793 - $390,748
-24,255 Closed
0 $0
Q2 2021

Aug 13, 2021

BUY
$11.44 - $13.57 $277,477 - $329,140
24,255 New
24,255 $329,000

Others Institutions Holding ELEV

About Elevation Oncology, Inc.


  • Ticker ELEV
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 23,300,900
  • Market Cap $14M
  • Description
  • Elevation Oncology, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for the treatment of cancer in genomically defined patient populations in the United States. The company's lead program is the seribantumab, an anti-HER3 monoclonal antibody that is in Phase II CRESTONE trial for the treatment of advanced sol...
More about ELEV
Track This Portfolio

Track Qube Research & Technologies LTD Portfolio

Follow Qube Research & Technologies LTD and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Qube Research & Technologies LTD, based on Form 13F filings with the SEC.

News

Stay updated on Qube Research & Technologies LTD with notifications on news.